Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 10, 2014 - Issue
Submit an article Journal homepage
97
Views
21
CrossRef citations to date
0
Altmetric
Review

Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection

Ivan Gentile1 Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyCorrespondence[email protected]
,
Antonio Riccardo Buonomo1 Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
,
Emanuela Zappulo1 Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
,
Giuseppina Minei1 Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
,
Filomena Morisco2 Section of Gastroenterology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
,
Francesco Borrelli1 Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
,
Nicola Coppola3 Section of Infectious Diseases, Department of Mental Health and Public Medicine, Second University of Naples, Naples, Italy
&
Guglielmo Borgia1 Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
 show all
Pages 493-504 | Published online: 26 Jun 2014

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Pravinkumar Vishwanath Ingle, Sarah Zakiah Samsudin, Pei Qi Chan, Mei Kei Ng, Li Xuan Heng, Siu Ching Yap, Amy Siaw Hui Chai & Audrey San Ying Wong. (2016) Development and novel therapeutics in hepatocellular carcinoma: a review. Therapeutics and Clinical Risk Management 12, pages 445-455.
Read now
Ivan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo, Riccardo Scotto & Guglielmo Borgia. (2015) Asunaprevir for hepatitis C: a safety evaluation. Expert Opinion on Drug Safety 14:10, pages 1631-1646.
Read now
Ivan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo, Alberto Enrico Maraolo & Guglielmo Borgia. (2015) Beclabuvir for the treatment of hepatitis C. Expert Opinion on Investigational Drugs 24:8, pages 1111-1121.
Read now
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo & Guglielmo Borgia. (2015) Discontinued drugs in 2012 – 2013: hepatitis C virus infection. Expert Opinion on Investigational Drugs 24:2, pages 239-251.
Read now
Sheng-Shun Yang & Jia-Horng Kao. (2015) Asunaprevir-containing regimens for the treatment of hepatitis C virus infection. Expert Review of Gastroenterology & Hepatology 9:1, pages 9-20.
Read now
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, Nicola Coppola & Guglielmo Borgia. (2014) GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection. Expert Review of Anti-infective Therapy 12:10, pages 1179-1186.
Read now

Articles from other publishers (15)

Jinhong Ren, Tasneem M. Vaid, Hyun Lee, Isabel Ojeda & Michael E. Johnson. (2022) Evaluation of interactions between the hepatitis C virus NS3/4A and sulfonamidobenzamide based molecules using molecular docking, molecular dynamics simulations and binding free energy calculations. Journal of Computer-Aided Molecular Design 37:1, pages 53-65.
Crossref
Chunying Luo, Maxwell Ampomah-Wireko, Huanhuan Wang, Chunli Wu, Qing Wang, Hui Zhang & Yaquan Cao. (2021) Isoquinolines: Important Cores in Many Marketed and Clinical Drugs. Anti-Cancer Agents in Medicinal Chemistry 21:7, pages 811-824.
Crossref
Prerana Shrestha, Pinar Ayata, Pedro Herrero-Vidal, Francesco Longo, Alexandra Gastone, Joseph E. LeDoux, Nathaniel Heintz & Eric Klann. (2020) Cell-type-specific drug-inducible protein synthesis inhibition demonstrates that memory consolidation requires rapid neuronal translation. Nature Neuroscience 23:2, pages 281-292.
Crossref
Riccardo Scotto, Antonio Riccardo Buonomo, Nicola Schiano Moriello, Alberto Enrico Maraolo, Emanuela Zappulo, Biagio Pinchera, Ivan Gentile & Guglielmo Borgia. (2019) Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection. Reviews on Recent Clinical Trials 14:3, pages 173-182.
Crossref
Yutai Li, Raymond Evers, Michael J Hafey, Kyeongmi Cheon, Hong Duong, Donna Lynch, Lisa LaFranco-Scheuch, Stephen Pacchione, Alex M Tamburino, Keith Q Tanis, Kristin Geddes, Daniel Holder, Nanyan Rena Zhang, Wen Kang, Raymond J Gonzalez, Alema Galijatovic-Idrizbegovic, Kara M Pearson, Jose A Lebron, Warren E Glaab & Frank D Sistare. (2019) Use of a Bile Salt Export Pump Knockdown Rat Susceptibility Model to Interrogate Mechanism of Drug-Induced Liver Toxicity. Toxicological Sciences 170:1, pages 180-198.
Crossref
Nicholas A. Meanwell, Ramkumar Rajamani, Paul M. Scola & Li-Qiang Sun. 2019. HCV: The Journey from Discovery to a Cure. HCV: The Journey from Discovery to a Cure 317 354 .
Petra E de Ruiter, Yashna Gadjradj, Robert J de Knegt, Herold J Metselaar, Jan NM Ijzermans & Luc JW van der Laan. (2018) Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir: combined effects with mycophenolic acid. World Journal of Transplantation 8:5, pages 156-166.
Crossref
Li Zhu, Hanbin Li, Phyllis Chan, Timothy Eley, Yash Gandhi, Marc Bifano, Mayu Osawa, Takayo Ueno, Eric Hughes, Malaz AbuTarif, Richard Bertz & Tushar Garimella. (2018) Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection. Infectious Diseases and Therapy 7:2, pages 261-275.
Crossref
Nikhil Pathak, Mei-Ling Lai, Wen-Yu Chen, Betty-Wu Hsieh, Guann-Yi Yu & Jinn-Moon Yang. (2017) Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV infection. BMC Bioinformatics 18:S16.
Crossref
Douglas D. Richman, Richard J. Whitley & Frederick J. HaydenMatthew L. Scherer, Chelsea Sammons, Brian Nelson, Scott M. Hammer & Elizabeth Verna. 2016. Clinical Virology. Clinical Virology 239 270 .
D. Banerjee & K. R. Reddy. (2016) Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Alimentary Pharmacology & Therapeutics 43:6, pages 674-696.
Crossref
Akihiro Tamori, Masaru Enomoto & Norifumi Kawada. (2016) Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators of Inflammation 2016, pages 1-11.
Crossref
Prarthana Thiagarajan & Stephen D. Ryder. (2015) The hepatitis C revolution part 1. Current Opinion in Infectious Diseases 28:6, pages 563-571.
Crossref
Satoshi Yoshimi, Michio Imamura, Eisuke Murakami, Nobuhiko Hiraga, Masataka Tsuge, Yoshiiku Kawakami, Hiroshi Aikata, Hiromi Abe, C. Nelson Hayes, Tamito Sasaki, Hidenori Ochi & Kazuaki Chayama. (2015) Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. Journal of Medical Virology 87:11, pages 1913-1920.
Crossref
Hui-Chun Li. (2015) Hepatitis C virus: Virology, diagnosis and treatment. World Journal of Hepatology 7:10, pages 1377.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.